Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$73.2 - $107.87 $2.31 Million - $3.4 Million
-31,543 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$60.45 - $84.26 $28,653 - $39,939
-474 Reduced 1.48%
31,543 $2.43 Million
Q1 2021

May 12, 2021

BUY
$58.19 - $91.37 $117,369 - $184,293
2,017 Added 6.72%
32,017 $2.12 Million
Q4 2020

Feb 16, 2021

BUY
$20.19 - $84.93 $605,700 - $2.55 Million
30,000 New
30,000 $2.55 Million
Q4 2019

Feb 14, 2020

SELL
$15.39 - $44.38 $988,176 - $2.85 Million
-64,209 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$21.55 - $27.61 $1.38 Million - $1.77 Million
64,209 New
64,209 $1.38 Million
Q4 2018

Feb 14, 2019

SELL
$11.19 - $18.56 $839,250 - $1.39 Million
-75,000 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$16.05 - $16.87 $1.2 Million - $1.27 Million
75,000 New
75,000 $1.27 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.32B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Pura Vida Investments, LLC Portfolio

Follow Pura Vida Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pura Vida Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pura Vida Investments, LLC with notifications on news.